Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-08-20

AUTHORS

Ana-Catarina Pinho-Gomes, John Cairns

ABSTRACT

This review discusses the methodological challenges to the evaluation of advanced therapy medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence (NICE). We analysed the health technology appraisals (both published and in development) of ATMPs conducted by NICE in England until July 2021. A total of 14 health technology appraisals of ATMPs were included, of which two were in development and 12 had been published. There were ten gene therapy products (talimogene laherparepvec [TA410], strimvelis [HST7], tisagenlecleucel [TA554 and TA567], axicabtagene ciloleucel [TA559], voretigene neparvovec [HST11], autologous anti-CD19-transduced CD3+ cells [TA677], betibeglogene autotemcel [ID968], onasemnogene abeparvovec [HST15] and OTL-200 [ID1666]), one tissue engineered product (holoclar [TA467]) and three somatic cell therapy products (darvadstrocel [TA556] and autologous chondrocyte implantation [ACI] [TA477 and TA508]). Only three of these technologies were not recommended by NICE, although four were only recommended within the Cancer Drugs Fund. There was large uncertainty in the assessment of clinical effectiveness, as evidence relied mostly on small, single-arm, open-label studies. There were also several concerns in the cost-effectiveness evaluations, such as limited information on health-related quality of life, immature survival data due to short follow-up, and unclear curative potential. Substantial risk may be incurred with ATMPs, which have high upfront and possibly irrecoverable costs but uncertain long-term benefits. In conclusion, the challenges raised by the economic appraisal of ATMPs, albeit not unique, may be exacerbated by the uncertainty related to the often scant evidence base. Adaptations of the conventional decision-making process rather than completely new methods may improve appraisals of ATMPs. More... »

PAGES

1-21

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41669-021-00295-2

DOI

http://dx.doi.org/10.1007/s41669-021-00295-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1140550473

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/34415514


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The George Institute for Global Health, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.476747.1", 
          "name": [
            "School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King\u2019s College London, SE1 1UL, London, UK", 
            "The George Institute for Global Health, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinho-Gomes", 
        "givenName": "Ana-Catarina", 
        "id": "sg:person.01276600765.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276600765.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "London School of Hygiene and Tropical Medicine, London, UK", 
          "id": "http://www.grid.ac/institutes/grid.8991.9", 
          "name": [
            "London School of Hygiene and Tropical Medicine, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cairns", 
        "givenName": "John", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10198-018-1007-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107079490", 
          "https://doi.org/10.1007/s10198-018-1007-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40259-020-00457-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1132846798", 
          "https://doi.org/10.1007/s40259-020-00457-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-019-01147-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1123979824", 
          "https://doi.org/10.1007/s10198-019-01147-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-019-01126-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122084664", 
          "https://doi.org/10.1007/s10198-019-01126-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11211-019-00333-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1113471923", 
          "https://doi.org/10.1007/s11211-019-00333-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-200624120-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037832218", 
          "https://doi.org/10.2165/00019053-200624120-00005"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-08-20", 
    "datePublishedReg": "2021-08-20", 
    "description": "This review discusses the methodological challenges to the evaluation of advanced therapy medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence (NICE). We analysed the health technology appraisals (both published and in development) of ATMPs conducted by NICE in England until July 2021. A total of 14 health technology appraisals of ATMPs were included, of which two were in development and 12 had been published. There were ten gene therapy products (talimogene laherparepvec [TA410], strimvelis [HST7], tisagenlecleucel [TA554 and TA567], axicabtagene ciloleucel [TA559], voretigene neparvovec [HST11], autologous anti-CD19-transduced CD3+ cells [TA677], betibeglogene autotemcel [ID968], onasemnogene abeparvovec [HST15] and OTL-200 [ID1666]), one tissue engineered product (holoclar [TA467]) and three somatic cell therapy products (darvadstrocel [TA556] and autologous chondrocyte implantation [ACI] [TA477 and TA508]). Only three of these technologies were not recommended by NICE, although four were only recommended within the Cancer Drugs Fund. There was large uncertainty in the assessment of clinical effectiveness, as evidence relied mostly on small, single-arm, open-label studies. There were also several concerns in the cost-effectiveness evaluations, such as limited information on health-related quality of life, immature survival data due to short follow-up, and unclear curative potential. Substantial risk may be incurred with ATMPs, which have high upfront and possibly irrecoverable costs but uncertain long-term benefits. In conclusion, the challenges raised by the economic appraisal of ATMPs, albeit not unique, may be exacerbated by the uncertainty related to the often scant evidence base. Adaptations of the conventional decision-making process rather than completely new methods may improve appraisals of ATMPs.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41669-021-00295-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1284515", 
        "issn": [
          "2509-4262", 
          "2509-4254"
        ], 
        "name": "PharmacoEconomics - Open", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }
    ], 
    "keywords": [
      "advanced therapy medicinal products", 
      "Care Excellence", 
      "somatic cell therapy products", 
      "therapy medicinal products", 
      "open-label study", 
      "technology appraisal", 
      "health-related quality", 
      "health technology appraisal", 
      "UK National Institute", 
      "National Institute", 
      "Cancer Drugs Fund", 
      "medicinal products", 
      "cost-effectiveness evaluation", 
      "therapy products", 
      "clinical effectiveness", 
      "long-term benefits", 
      "curative potential", 
      "substantial risk", 
      "evidence base", 
      "cell therapy products", 
      "Drugs Fund", 
      "scant evidence base", 
      "survival data", 
      "updated review", 
      "uncertain long-term benefits", 
      "high upfront", 
      "gene therapy products", 
      "health", 
      "limited information", 
      "NICE", 
      "review", 
      "evaluation", 
      "total", 
      "risk", 
      "tissue", 
      "Institute", 
      "upfront", 
      "appraisal", 
      "conclusion", 
      "assessment", 
      "evidence", 
      "methodological challenges", 
      "decision-making process", 
      "economic appraisal", 
      "study", 
      "life", 
      "benefits", 
      "challenges", 
      "excellence", 
      "concern", 
      "data", 
      "development", 
      "quality", 
      "effectiveness", 
      "products", 
      "potential", 
      "adaptation", 
      "England", 
      "irrecoverable costs", 
      "information", 
      "method", 
      "base", 
      "cost", 
      "new method", 
      "process", 
      "funds", 
      "uncertainty", 
      "technology", 
      "large uncertainties", 
      "immature survival data", 
      "unclear curative potential", 
      "conventional decision-making process", 
      "appraisals of ATMPs"
    ], 
    "name": "Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review", 
    "pagination": "1-21", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1140550473"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41669-021-00295-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "34415514"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41669-021-00295-2", 
      "https://app.dimensions.ai/details/publication/pub.1140550473"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_919.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41669-021-00295-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00295-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00295-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00295-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41669-021-00295-2'


 

This table displays all metadata directly associated to this object as RDF triples.

163 TRIPLES      22 PREDICATES      103 URIs      89 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41669-021-00295-2 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author N14615815622d45049b581429243ee947
4 schema:citation sg:pub.10.1007/s10198-018-1007-x
5 sg:pub.10.1007/s10198-019-01126-2
6 sg:pub.10.1007/s10198-019-01147-x
7 sg:pub.10.1007/s11211-019-00333-9
8 sg:pub.10.1007/s40259-020-00457-4
9 sg:pub.10.2165/00019053-200624120-00005
10 schema:datePublished 2021-08-20
11 schema:datePublishedReg 2021-08-20
12 schema:description This review discusses the methodological challenges to the evaluation of advanced therapy medicinal products (ATMPs) by the UK National Institute for Health and Care Excellence (NICE). We analysed the health technology appraisals (both published and in development) of ATMPs conducted by NICE in England until July 2021. A total of 14 health technology appraisals of ATMPs were included, of which two were in development and 12 had been published. There were ten gene therapy products (talimogene laherparepvec [TA410], strimvelis [HST7], tisagenlecleucel [TA554 and TA567], axicabtagene ciloleucel [TA559], voretigene neparvovec [HST11], autologous anti-CD19-transduced CD3+ cells [TA677], betibeglogene autotemcel [ID968], onasemnogene abeparvovec [HST15] and OTL-200 [ID1666]), one tissue engineered product (holoclar [TA467]) and three somatic cell therapy products (darvadstrocel [TA556] and autologous chondrocyte implantation [ACI] [TA477 and TA508]). Only three of these technologies were not recommended by NICE, although four were only recommended within the Cancer Drugs Fund. There was large uncertainty in the assessment of clinical effectiveness, as evidence relied mostly on small, single-arm, open-label studies. There were also several concerns in the cost-effectiveness evaluations, such as limited information on health-related quality of life, immature survival data due to short follow-up, and unclear curative potential. Substantial risk may be incurred with ATMPs, which have high upfront and possibly irrecoverable costs but uncertain long-term benefits. In conclusion, the challenges raised by the economic appraisal of ATMPs, albeit not unique, may be exacerbated by the uncertainty related to the often scant evidence base. Adaptations of the conventional decision-making process rather than completely new methods may improve appraisals of ATMPs.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf sg:journal.1284515
17 schema:keywords Cancer Drugs Fund
18 Care Excellence
19 Drugs Fund
20 England
21 Institute
22 NICE
23 National Institute
24 UK National Institute
25 adaptation
26 advanced therapy medicinal products
27 appraisal
28 appraisals of ATMPs
29 assessment
30 base
31 benefits
32 cell therapy products
33 challenges
34 clinical effectiveness
35 concern
36 conclusion
37 conventional decision-making process
38 cost
39 cost-effectiveness evaluation
40 curative potential
41 data
42 decision-making process
43 development
44 economic appraisal
45 effectiveness
46 evaluation
47 evidence
48 evidence base
49 excellence
50 funds
51 gene therapy products
52 health
53 health technology appraisal
54 health-related quality
55 high upfront
56 immature survival data
57 information
58 irrecoverable costs
59 large uncertainties
60 life
61 limited information
62 long-term benefits
63 medicinal products
64 method
65 methodological challenges
66 new method
67 open-label study
68 potential
69 process
70 products
71 quality
72 review
73 risk
74 scant evidence base
75 somatic cell therapy products
76 study
77 substantial risk
78 survival data
79 technology
80 technology appraisal
81 therapy medicinal products
82 therapy products
83 tissue
84 total
85 uncertain long-term benefits
86 uncertainty
87 unclear curative potential
88 updated review
89 upfront
90 schema:name Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review
91 schema:pagination 1-21
92 schema:productId N10605631fb3e4a1ca75b495fa62232c1
93 N56639f7eca1e46cca22f31ec8001904e
94 Nd8592365964a4c2fae4e25567be53544
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140550473
96 https://doi.org/10.1007/s41669-021-00295-2
97 schema:sdDatePublished 2022-01-01T19:01
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher N6a1eade277f14ca796cea997a6eff996
100 schema:url https://doi.org/10.1007/s41669-021-00295-2
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N08c477bf7b644ddfbd47de1903b4d921 schema:affiliation grid-institutes:grid.8991.9
105 schema:familyName Cairns
106 schema:givenName John
107 rdf:type schema:Person
108 N10605631fb3e4a1ca75b495fa62232c1 schema:name dimensions_id
109 schema:value pub.1140550473
110 rdf:type schema:PropertyValue
111 N14615815622d45049b581429243ee947 rdf:first sg:person.01276600765.45
112 rdf:rest Nfc621497028048688ea2e29aad9e3f5c
113 N56639f7eca1e46cca22f31ec8001904e schema:name doi
114 schema:value 10.1007/s41669-021-00295-2
115 rdf:type schema:PropertyValue
116 N6a1eade277f14ca796cea997a6eff996 schema:name Springer Nature - SN SciGraph project
117 rdf:type schema:Organization
118 Nd8592365964a4c2fae4e25567be53544 schema:name pubmed_id
119 schema:value 34415514
120 rdf:type schema:PropertyValue
121 Nfc621497028048688ea2e29aad9e3f5c rdf:first N08c477bf7b644ddfbd47de1903b4d921
122 rdf:rest rdf:nil
123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
124 schema:name Medical and Health Sciences
125 rdf:type schema:DefinedTerm
126 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
127 schema:name Public Health and Health Services
128 rdf:type schema:DefinedTerm
129 sg:journal.1284515 schema:issn 2509-4254
130 2509-4262
131 schema:name PharmacoEconomics - Open
132 schema:publisher Springer Nature
133 rdf:type schema:Periodical
134 sg:person.01276600765.45 schema:affiliation grid-institutes:grid.476747.1
135 schema:familyName Pinho-Gomes
136 schema:givenName Ana-Catarina
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276600765.45
138 rdf:type schema:Person
139 sg:pub.10.1007/s10198-018-1007-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1107079490
140 https://doi.org/10.1007/s10198-018-1007-x
141 rdf:type schema:CreativeWork
142 sg:pub.10.1007/s10198-019-01126-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122084664
143 https://doi.org/10.1007/s10198-019-01126-2
144 rdf:type schema:CreativeWork
145 sg:pub.10.1007/s10198-019-01147-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1123979824
146 https://doi.org/10.1007/s10198-019-01147-x
147 rdf:type schema:CreativeWork
148 sg:pub.10.1007/s11211-019-00333-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113471923
149 https://doi.org/10.1007/s11211-019-00333-9
150 rdf:type schema:CreativeWork
151 sg:pub.10.1007/s40259-020-00457-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132846798
152 https://doi.org/10.1007/s40259-020-00457-4
153 rdf:type schema:CreativeWork
154 sg:pub.10.2165/00019053-200624120-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037832218
155 https://doi.org/10.2165/00019053-200624120-00005
156 rdf:type schema:CreativeWork
157 grid-institutes:grid.476747.1 schema:alternateName The George Institute for Global Health, London, UK
158 schema:name School of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King’s College London, SE1 1UL, London, UK
159 The George Institute for Global Health, London, UK
160 rdf:type schema:Organization
161 grid-institutes:grid.8991.9 schema:alternateName London School of Hygiene and Tropical Medicine, London, UK
162 schema:name London School of Hygiene and Tropical Medicine, London, UK
163 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...